Home / Market News / $OMAB

$OMAB news and market catalysts

The 7 most recent market catalysts affecting $OMAB, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.

7 catalysts 3 high impact 4 bullish 1 bearish Biotechnology
Oct 30, 2026 Corporate Catalyst Bearish Impact 85
OmniAb Reports Third Quarter 2026 Financial Results and Business Highlights
OmniAb announced its Q3 2026 earnings, reporting revenue of $4.0 million against an estimated $3.5 million, and a net loss of $0.12 per share, better than the anticipated $0.13 los…
Oct 6, 2026 Corporate Catalyst Bullish Impact 75
OmniAb Expects 2026 xPloration Platform Revenue Of $2M-$3M, Doubling In 2027 And Again In 2028
This headline is a significant corporate catalyst for OmniAb (OMAB). The projected revenue of $2M-$3M in 2026, doubling in 2027 and again in 2028, signals robust growth for their x…
Aug 17, 2026 Corporate Catalyst Bullish Impact 85
OmniAb shares are trading higher after the company revised its FY26 Cash and Cash Equivalent guidance above prior expectations. The company announced a a global collaboration and license agreement with Eli Lilly and Company for a new ion channel program.
This headline is a strong positive catalyst for OmniAb. The revised FY26 cash guidance indicates a healthier financial outlook, while the collaboration with Eli Lilly, a pharmaceut…
Aug 17, 2026 Corporate Catalyst Bullish Impact 75
Omniab Revises 2026 Cash and Cash Equivalents Financial Guidance to Between $49M and $53M Vs. $37-$41M Previously
This headline represents a significant corporate catalyst for Omniab. The upward revision of 2026 cash and cash equivalents guidance by a substantial margin (from $37-$41M to $49-$…
Aug 17, 2026 Corporate Catalyst Neutral Impact 65
OmniAb Announces Global Collaboration and License Agreement with Eli Lilly For New Ion Channel Program; OmniAb To Receive An Upfront Payment and Is Eligible To Receive Up to $370M In R&D and Commercial Milestone Payments
OmniAb announced a global collaboration and license agreement with Eli Lilly for an undisclosed ion channel program. This deal includes an upfront payment to OmniAb and potential m…
Aug 7, 2026 Corporate Catalyst Bullish Impact 92
OmniAb shares are trading higher after the company reported better-than-expected Q2 financial results. The company also raised its FY2026 sales guidance above estimates.
This headline represents a strong positive corporate catalyst for OmniAb. Better-than-expected earnings and, crucially, raised future guidance signal robust operational performance…
Jul 13, 2026 Corporate Catalyst Neutral Impact 55
OmniAb Names Amechi Nwachuku To Newly-Created Position Of Executive Vice President And COO
The appointment of an Executive Vice President and COO at OmniAb is a moderate corporate catalyst. This newly created position suggests the company is prioritizing operational exce…
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.